PURPOSE: @entity157 ( @entity157 ) is one of the most common @entity5 worldwide. Because @entity157 usually presents as an advanced disease and occurs in the background of liver @entity82 , most @entity1 are not suitable for treatment with curative intent, thus effective systemic chemotherapy is required. However, the outcome of systemic chemotherapy has been disappointing in advanced @entity157 . This study was conducted to test the efficacy and @entity137 of the combined regimen of @entity1259 , @entity900 , and UFT moderated by @entity4181 in advanced or recurrent @entity157 . @entity1 AND METHODS: All 53 @entity1 received @entity1259 (50 mg/m2 i.v.) on day 1 and @entity900 (60 mg/m2 i.v.) after @entity1259 administration. Oral UFT 400-600 mg/day, determined by body surface area, and @entity4181 75 mg/day were administered for 21 consecutive days, followed by a 7-day drug free interval. RESULTS: Nine had a partial response, representing 16.9% of response rate (95% confidence interval rate; 7.0-26.8%) with median response duration of 17.1 weeks (95% CI; 5.0-29.3 weeks, range; 7.1-51.7 weeks). Fifteen @entity1 had stable disease and the disease progressed in 26 @entity1 . The median overall survival for the @entity1 was 24.6 weeks (95% CI; 17.3-31.9 weeks, range; 3.0-131.3 weeks). The main @entity137 were hematologic @entity137 including @entity1398 , which reached grade 3/4 in 17 @entity1 (38.5%), and grade 3 or 4 @entity882 in five @entity1 (9.4%). CONCLUSION: The combination of @entity1259 , @entity900 , and UFT moderated by @entity4181 showed modest anti- @entity5 activity with relatively tolerable @entity137 . However, a randomized phase III trial based on this regimen is warranted to clarify its survival benefit in @entity1 with advanced @entity157 .

Phase II study with a combination of XXXX , @entity900 , UFT, and @entity4181 in advanced @entity157 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma']
@entity1259 :: (MESH:D015251,Chemical) :: ['epirubicin']
